Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 711

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 711
---
 that orexin receptor pathways are involved in pathological processes of neurological diseases such as obesity, narcolepsy, depression, ischemic stroke, Annex F-65 drug addiction and Alzheimer’s disease. These new compounds, in addition to our current pipeline, including Mazindol ER for the treatment of narcolepsy, NLS -4focused on idiopathic hypersomnia, long -COVIDand chronic fatigue syndrome, and NLS -11, addressing Kleine -LevinSyndrome and neurodegenerative diseases, will further complement and strengthen our sleep franchise. NLS will be uniquely positioned to hold the key to unlock the challenges associated with rare sleep disorders now and in the future. In addition, we initiated a comprehensive exploration of new opportunities that align with our core values and strengths, with the goal of diversifying our revenue streams, mitigating risks and creating lasting value for our stakeholders. As part of this process, the Company is considering a wide range of options with a focus on maximizing shareholder value, including strategic partnerships, out licensing assets of the Company, and other future strategic actions. Several strategic partnerships discussions are currently under way and in advanced stages of negotiations. As always, we continue to approach the sleep medicine market from a holistic perspective. According to Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments — Forecast to 2030” the global sleep medicine market is estimated to increase to more than $100 billion by 2030, with narcolepsy accounting for over $6 billion by 2030. License Agreements Pegasus Advanced Research SAS License Agreement In February 2015, Pegasus Advanced Research, then named NeuroLife -SciencesSAS, or Pegasus, a company owned by certain of our founders, who are also shareholders, including Eric Konofal, Eric -JeanDesbois, Bruno Figadere and our Chief Executive Officer, Alexander Zwyer, or the Pegasus Founders, entered into a license agreement with AP -HP, or the AP -HPLicense Agreement, to obtain a worldwide, sub -licensablelicense, covering four different compounds, which included the use of mazindol for the treatment of ADHD, or the Licensed Compounds. As part of the AP -HPLicense Agreement, Pegasus was given an option to purchase the Licensed Compounds. In February 2016, after the AP -HPLicense Agreement was assigned and transferred to NLS -1